Clinical Trials Logo

Filter by:
NCT ID: NCT06434350 Not yet recruiting - Clinical trials for Advanced Bladder Cancer

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Start date: November 29, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.

NCT ID: NCT06434337 Not yet recruiting - Clinical trials for Human Papillomavirus

Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)

Start date: November 29, 2024
Phase:
Study type: Observational

To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.

NCT ID: NCT06434324 Not yet recruiting - Pleural Infection Clinical Trials

Pleural Space Saline Irrigation in Addition to Standard Intrapleural Thrombolytic Therapy in Empyema/Complicated Parapneumonic Effusion

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to see if there is any benefit in adding saline irrigation through a chest tube to the standard course of treatment for people diagnosed or suspected of having a pleural space infection.

NCT ID: NCT06434207 Not yet recruiting - Clinical trials for Congenital Heart Disease

Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis

EVmiRNA
Start date: June 1, 2024
Phase:
Study type: Observational

Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. The molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described. The goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (CHD) to better understand mechanisms responsible for abnormal clotting in the perioperative period.

NCT ID: NCT06434168 Not yet recruiting - Heart Failure Clinical Trials

Impact of Yoga on Cognitive Function

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Mild cognitive impairment is highly prevalent in patients with heart failure and results in poor well-being and quality of life. While yoga has proven effective in promoting cognitive health in older adults through its gentle movements, controlled breathing, and meditation, its effects on patients with heart failure remain unknown. Therefore, this feasibility and pilot study plans to deliver a 12-week yoga intervention and test its effects on cognitive function in patients with heart failure and mild cognitive impairment.

NCT ID: NCT06434064 Not yet recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Start date: June 30, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well tamoxifen and pegylated liposomal doxorubicin works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that has spread to nearby tissue or lymph nodes (locally advanced) and is unable to be operated on (inoperable). Tamoxifen works by blocking the effects of estrogen in the breast. This may help stop the growth of tumor cells that need estrogen to grow. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving tamoxifen and pegylated liposomal doxorubicin together may work better in treating patients with metastatic or inoperable, locally advanced triple negative breast cancer than giving either of these drugs alone.

NCT ID: NCT06434038 Not yet recruiting - Healthy Clinical Trials

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

INI-CSF-MA
Start date: October 1, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, reaches the brain and spinal cord when delivered as a nasal spray (intranasally). Intranasal insulin has been shown to improve memory and mood in patients with neurological diseases such as mild cognitive impairment and dementia, but more evidence is needed to support the ability to effectively target the brain through intranasal routes. 18 healthy middle-aged adults will be randomly assigned to receive a single intranasal dose of 40 units insulin ("low dose" group), 80 units insulin ("high dose" group), or saline (placebo, or control group). Participants will undergo an image-guided lumbar puncture (spinal tap) performed by a study clinician. Samples of cerebrospinal fluid (a fluid surrounding the brain and spinal cord) and blood will be collected at 5 timepoints during the lumbar puncture: once prior to the administration of intranasal insulin, and again at 10, 20, 30, and 40 minutes after the dose is given. Samples will be tested to determine the level of insulin detected in the cerebrospinal fluid and blood at each time point. Results of this study will provide essential information about the ability of insulin to reach the brain after intranasal administration.

NCT ID: NCT06433947 Not yet recruiting - Clinical trials for Refractory Multiple Myeloma

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.

NCT ID: NCT06433934 Not yet recruiting - Hypoxia Clinical Trials

Comparison of the Oxymask and Oxy2mask on Supplemental Oxygen Delivery

Start date: June 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the performance of a newly released oxygen mask is the same, better, or worse than previous mask version. We will measure the flow rate necessary to maintain the same oxygen saturation in adult patients using each mask.

NCT ID: NCT06433791 Not yet recruiting - Safety Clinical Trials

Evaluation of Ascorbate-Meglumine Therapeutic for SRS

Start date: June 17, 2024
Phase: Phase 1
Study type: Interventional

Phase 1, Single-Center, Dose-Escalating, Open-Label, Safety Clinical Trial of Parenteral Ascorbate-Meglumine as a Novel Magnetic Resonance Imaging (MRI)-guided Adjunctive Therapeutic for Stereotactic Radiosurgery (SRS)